Titlebook: Unusual Cases in Peritoneal Surface Malignancies; Emel Canbay Book 2017 Springer International Publishing AG 2017 Peritoneal Metastases.Cy

Clinch

,Peritoneal Metastasis from Small Bowel Adenocarcinoma Associated with Crohn’s Disease,alls. CD most often involves the small intestine and colon. Over the past decades, intestinal adenocarcinoma has been recognized as a complication of CD. The management of patients with peritoneal metastasis (PM) of small bowel adenocarcinoma (SBA) associated with Crohn’s disease (CD) has not been d

ostrish

虛假

啤酒

Management of Desmoplastic Small Round Cell Tumor,organ or specific tissue type of origin is unknown. It is rarely isolated to one tumor implant in the abdomen and in most cases presents with dozens to hundreds of abdominal peritoneal tumors. One very large dominant mass is usually present in the omentum with the second and third largest conglomera

過(guò)于光澤

ESO

The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST,rointestinal tumors. The annual incidence is 10–13 per 1,000,000, with the majority arising in the stomach (50–60%) and small bowel (20–30%) and only a minority in the large bowel (5%) and esophagus (<5%) [1, 2]. GISTs arise from activating mutations of tyrosine kinase receptors, most commonly by KI

alcohol-abuse

Book 2017from different primaries, such as breast cancer, small bowel cancers and imatinib resistant GISTosis and sarcomas and pseudomyxoma. The book provides the most up-to-date information on current approaches such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.?Given the increasin

修飾語(yǔ)

rs.Chapters explore cytoreductive surgery and HIPEC, which a.This book has been designed to provide the full description of the comprehensive management of peritoneal surface malignancies which have?originated from different primaries, such as breast cancer, small bowel cancers and imatinib resistan

壓迫

Bouquet

The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST,o known mutation in KIT or PDGRF and are wild type. The treatment of GISTs has dramatically changed since 2002 due to the FDA approval of imatinib/Gleevec, a tyrosine kinase inhibitor (TKI) of c-KIT. Imatinib has initial response rates of 75–80% [3].